Immuto Scientific

Immuto Scientific is a biotechnology company that specializes in structural proteomics and drug target discovery, with a primary focus on oncology. Founded by electrical engineers, the company employs a proprietary, AI-enabled platform that integrates mass spectrometry with radical-based protein labeling to map structural changes in cell surface proteins. This technology, referred to as structural surfaceomics, identifies disease-specific protein conformations—often invisible to traditional methods—to pinpoint novel, targetable epitopes. By leveraging these insights, the company develops first-in-class biologics and therapies designed to be highly specific to diseased tissues while sparing healthy ones, aiming to overcome efficacy and toxicity limitations common in existing clinical approaches.

The company provides significant value to the biopharmaceutical industry by addressing the structural data bottlenecks in drug development. Through its high-throughput platform, Immuto Scientific collaborates with academic institutions, biotechnology, and pharmaceutical partners to accelerate the discovery of novel therapeutic targets. In addition to internal pipeline programs focused on cancers such as acute myeloid leukemia and colorectal cancer, the company utilizes its structural intelligence to enhance AI-driven antibody design and discovery workflows. By bridging the gap between biological complexity and engineering, Immuto seeks to transform drug discovery from a process dependent on genetic mutation data into one informed by the structural architecture of proteins in their native disease context.